Cantor Fitzgerald Forecasts AARD FY2026 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Aardvark Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($2.52) for the year. Cantor Fitzgerald has a “Overweight” rating and a $50.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. Royal Bank of Canada lowered their target price on Aardvark Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Wall Street Zen raised shares of Aardvark Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Bank of America boosted their target price on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. Finally, Morgan Stanley started coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They set an “overweight” rating and a $29.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Aardvark Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.25.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ:AARD opened at $11.68 on Tuesday. Aardvark Therapeutics has a 1 year low of $4.88 and a 1 year high of $19.58. The company has a 50-day simple moving average of $9.57.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01).

Institutional Trading of Aardvark Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Decheng Capital LLC bought a new position in shares of Aardvark Therapeutics in the first quarter valued at $29,419,000. Walleye Capital LLC purchased a new stake in Aardvark Therapeutics in the 1st quarter valued at about $88,000. Braidwell LP bought a new position in shares of Aardvark Therapeutics during the 1st quarter worth approximately $3,755,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Aardvark Therapeutics during the 1st quarter worth approximately $1,878,000. Finally, Cormorant Asset Management LP purchased a new stake in shares of Aardvark Therapeutics during the first quarter valued at approximately $6,009,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.